JAK2 and myeloproliferative neoplasm: In 2005, a major advance in the understanding of the pathogenesis of MPN occurred when JAK2V617F, a clonal recurrent point mutation in the pseudokinase domain of JAK2, was identified in many patients with MPN [4–8].